The calming-products story is getting louder. The market response has been quieter.
The Calmer Co International (ASX:CCO) is trying to turn kava, a Pacific Islands product long used for relaxation, into a broader consumer and ingredients business across Australia, the US and other markets. Its brands include Fiji Kava, Taki Mai and Danodan Hempworks, with products spanning powders, capsules, ready-to-drink formats and extracts.
That is the clean version. The more interesting version is that Calmer Co now looks less like a small wellness brand hoping for shelf space and more like a tiny listed company trying to prove that kava can travel through several channels at once: retail, e-commerce, wholesale and B2B ingredients.
The question is not whether the story is easy to understand. It is whether the numbers can become repeatable enough for the market to care.
The US Is Becoming the Centre of the Story
Calmer Co’s Q3 FY26 update gave investors one useful signal: the US is no longer a side note. The company reported A$1.96 million of Q3 FY26 revenue, broadly in line with the previous quarter, with temporary retail channel disruption and wholesale shipment timing affecting the result. The US contributed 59% of group revenue, supported by partner demand and broader e-commerce and wholesale distribution.
That matters because the US market is where the company’s kava pitch has the most room to stretch. In Australia, the brand has supermarket exposure and consumer recognition to build from. In the US, the business is more about whether kava can find repeat buyers through Amazon, wholesale partners and ingredient demand.
The March number was the cleaner detail. Calmer Co said it achieved a record monthly sales result of A$1.2 million, helped by the timing and scale of wholesale orders.
One month does not make a trend. But it does show the business can print a larger sales number when the wholesale cycle lines up.
Wholesale Is Doing the Heavy Lifting
The most useful part of the Q3 update was not total revenue. It was mix.
Wholesale revenue rose 78% quarter on quarter to A$645,783, with demand for traditional kava formats and high-potency CO₂ extracts. That points to a different version of Calmer Co than the simple consumer-brand story. A direct-to-consumer wellness brand needs marketing spend, repeat purchase and retail execution. An ingredients business needs supply, quality control and reliable customers.
The company wants both. That is appealing on paper because it gives Calmer Co more than one route to growth. It is also the operational challenge. Retail wants brand investment. Wholesale wants consistency and working capital. Ingredients customers want reliability before they scale orders.
The company’s FY25 result gives the growth story some base. Its February 2026 placement material said FY25 revenue was A$8 million, up 86% year on year and nearly five times higher over two years. The half-year to 31 December 2025 then produced A$4.43 million of revenue, while the company reduced its net loss by A$620,000 compared with the previous year.
That is progress. It is not yet proof of a settled model.
The Share Price Is Asking a Harder Question
For all the operating momentum, the share price has not behaved like a market convinced. Market Index recently showed CCO at A$0.002, with a market capitalisation of about A$7.04 million, down 20% over one month and 50% for 2026 year to date.
That gap is the article.
Supporters can point to a company that has grown revenue from a small base, pushed deeper into the US, built wholesale momentum and raised fresh capital. Calmer Co completed a A$1.6 million placement in February 2026 to support strategic growth, including US expansion. It also secured a FJ$548,000 non-repayable Fiji Government grant in March 2026.
Sceptics can point to the same facts and ask whether the business is still too small, too thinly capitalised and too dependent on lumpy channel timing. The FY25 annual report carried a material uncertainty related to going concern, noting a A$3.99 million loss before tax, accumulated losses of A$33.38 million and operating cash outflows of A$4.37 million.
That does not cancel the growth story. It sets the hurdle.
Cash Flow Is the Real Product Test
Calmer Co says it is focused on cost management, working capital discipline and progress toward cash flow breakeven. That is where the next phase of the story sits.
For investors watching from the outside, the key test is not whether kava has a cleaner narrative than alcohol alternatives or sleep supplements. The test is whether Calmer Co can turn the March sales spike and US wholesale momentum into a more predictable run rate.
The next quarterly update needs to show whether US demand is repeating, whether wholesale orders are becoming less lumpy, and whether cash burn is narrowing as revenue scales.
The story is easy to like. The accounts still have to make it harder to doubt.
